Loading the section
Closing prices for 09 October 2026
Next earnings report: 19 October 2026 · Earnings calendar
The series is stated in the current share scale after splits; dividends are not included in the price
Summit Therapeutics Inc. trades on Nasdaq under the ticker SMMT. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks SMMT has traded between 12.07 $ and 29.23 $. As of 09 October 2026 the price stood 32.17 % of the way from the 52-week low to the high.
Over one year SMMT shares fell 24.64 %; over six months they fell 10.57 %. Volatility over 90 days is 64.27 %. Dividends are not included: this is price change only, as of 09 October 2026.
The company reported a loss over the last four quarters, so a price-to-earnings ratio is not calculated. Price to book is 24.6, above the sector median of 2.4. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 09 October 2026 | 17.36 | 17.62 | 16.82 | 17.59 | 6M |
| 08 October 2026 | 17.61 | 17.64 | 16.80 | 17.17 | 6M |
| 07 October 2026 | 17.10 | 18.33 | 16.98 | 17.95 | 8M |
| 06 October 2026 | 17.49 | 17.53 |
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
Summit Therapeutics is testing a lung cancer drug whose rights were bought from a Chinese developer.
The molecule acts on two targets at once, combining the mechanisms of two drug classes in one. In trials run in China it outperformed the current standard of care — a result that, if confirmed in international studies, changes oncology practice.
That is precisely where the whole question lies: regulators elsewhere treat data from a single country cautiously, and confirmatory studies take years. The company has neither revenue nor an approved drug, and its valuation entirely reflects the probability of success. The risk is binary: confirmation and failure move the value several times over. Funding comes from share issuance.
Address:601 BRICKELL KEY DRIVE SUITE 1000, MIAMI, FL, 33131, US
Summit Therapeutics Inc. reported revenue of 0 $ and a net loss of 1.2B $ over the last four quarters. Earnings per share are −1.59 $. Market capitalisation is 13.4B $.
SMMT has a return on equity of −220.92 %, below the sector median of −41.68 %. Return on assets is −186.17 %, below the sector median of −32.11 %.
| 1.2B |
| PFEPfizer, Inc. | 28.18 | +1.28 % | 929M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 16.53 |
| 17.31 |
| 6M |
| 05 October 2026 | 16.97 | 17.62 | 16.44 | 17.27 | 5M |
| 02 October 2026 | 16.96 | 17.32 | 16.66 | 16.76 | 5M |
| 01 October 2026 | 16.82 | 17.50 | 16.59 | 16.69 | 8M |
| 30 September 2026 | 16.59 | 17.72 | 16.17 | 16.91 | 13M |
| 29 September 2026 | 18.91 | 19.09 | 16.15 | 16.39 | 27M |
| 28 September 2026 | 15.50 | 15.82 | 15.18 | 15.48 | 6M |
| 25 September 2026 | 16.45 | 16.58 | 15.55 | 15.61 | 4M |
| 24 September 2026 | 16.37 | 16.78 | 16.09 | 16.38 | 5M |
| 23 September 2026 | 17.10 | 17.46 | 16.25 | 16.45 | 4M |
| 22 September 2026 | 16.97 | 17.50 | 16.79 | 17.12 | 5M |
| 21 September 2026 | 18.40 | 18.42 | 16.64 | 16.90 | 6M |
| 18 September 2026 | 17.74 | 17.87 | 17.31 | 17.85 | 13M |
| 17 September 2026 | 17.73 | 18.10 | 17.42 | 17.72 | 6M |
| 16 September 2026 | 17.50 | 17.75 | 17.11 | 17.30 | 6M |
| 15 September 2026 | 18.16 | 18.47 | 17.11 | 17.40 | 6M |
| 14 September 2026 | 18.07 | 18.83 | 17.97 | 18.42 | 7M |